

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Zoon *et al.*

Application No.

Filed: Herewith

For: INTERFERON ALPHA HYBRIDS

Examiner: Not yet assigned.

Date: July 8, 2003

Art Unit: Not yet assigned.

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on July 8, 2003 as Express Mail Label No. EV339203210US in an envelope addressed to: MAIL STOP PATENT APPLICATION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Tanya M. Harding, Ph.D.  
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT  
FOR CONTINUING APPLICATIONS

MAIL STOP PATENT APPLICATION  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 are several English-language documents.

Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/744,754, which was filed January 24, 2001, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application.

Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicants or the Patent Office in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicants will furnish the Patent Office with such copies upon request.

Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of the transmittal letter is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in Rule 56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.  
Registration No. 42,630

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Attorney Docket Number</b>	4239-64129
	<b>Application Number</b>	Not yet assigned.
	<b>Filing Date</b>	Concurrent herewith
	<b>First Named Inventor</b>	Zoon
	<b>Art Unit</b>	Not yet assigned.
	<b>Examiner Name</b>	Not yet assigned.

**U.S. PATENT DOCUMENTS**

<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>Number</b>	<b>Date</b>	<b>Name</b>
		4,569,908	2/11/1986	Mark
		4,716,217	12/29/1987	Caruthers
		4,758,428	7/19/1988	Mark
		4,806,347	2/21/1989	Leibowitz
		4,820,638	4/11/1989	Swetly
		4,885,166	12/5/1989	Meyer
		4,892,743	1/9/1990	Leibowitz
		4,914,033	4/3/1990	Bell
		4,917,887	4/17/1990	Hauptmann
		5,071,761	12/10/1991	Meyer
		5,089,400	2/18/1992	Meyer
		5,593,667	1/14/1997	Kung
		5,609,868	3/11/1997	Lowther

**FOREIGN PATENT DOCUMENTS**

<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>Number</b>	<b>Date</b>	<b>Country</b>
		0626448A	30 Nov 1994	EP

<b>EXAMINER SIGNATURE:</b>	<b>DATE CONSIDERED:</b>
--------------------------------	-----------------------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

<b>Attorney Docket Number</b>	4239-64129
<b>Application Number</b>	Not yet assigned.
<b>Filing Date</b>	Concurrent herewith
<b>First Named Inventor</b>	Zoon
<b>Art Unit</b>	Not yet assigned.
<b>Examiner Name</b>	Not yet assigned.

<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>
		Alexanko <i>et al.</i> , "Mapping of an epitope of human leukocyte alpha interferon A which is recognized by the murine monoclonal antibody NK2," <i>Biomed. Sci.</i> , 2(4):403-409, 1991
		Alexanko <i>et al.</i> , "Reconstruction of an epitope capable of binding murine monoclonal antibodies NK2 within the sequence of human leukocyte interferon alpha F by site-directed mutagenesis," <i>Biochem. Biophys. Res. Commun.</i> , 169(3):1061-1067, June 29, 1990
		Allen <i>et al.</i> , "Nomenclature of the Human Interferon Proteins," <i>J. Interferon Cytokine Res.</i> , 16:181-184, 1996
		Di Marco <i>et al.</i> , "Mutational analysis of the structure-function relationship in interferon-alpha," <i>Biochem. Biophys. Res. Comm.</i> , 202(3):1445-1451, 15 August 1994
		Fidler <i>et al.</i> , "Direct antiproliferative effects of recombinant human interferon-alpha B/D hybrids on human tumor cell lines," <i>Cancer Res.</i> , 47(8):2020-2027, April 15, 1987
		Fish <i>et al.</i> , "Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells," <i>Biochem. Biophys. Res. Commun.</i> , 112(2):537-546, April 29, 1983
		Goeddel <i>et al.</i> , "The structure of eight distinct cloned human leukocyte interferon cDNAs," <i>Nature, GB, Macmillan Journals Ltd. London</i> , 290:20-26, 5 March 1981
		Horisberger and Di Marco., "Interferon-alpha hybrids," <i>Pharmac. Ther.</i> 66(3):507-534, 1995
		Hu <i>et al.</i> , "Divergence of Binding, Signaling, and Biological Responses to Recombinant Human Hybrid IFN," <i>J. Immunol.</i> , 16(2):854-860, 15 July 1999
		Horton <i>et al.</i> , "Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension," <i>Gene, NL, Elservier Biomedical Press, Amsterdam</i> , 77:61-68, 1989
		Hu <i>et al.</i> , "HuIFNalpha21 gene expression and properties of recombinant IFNalpha21," <i>J. Interferon Res.</i> , 14(suppl):S98, September 1994
		Meister <i>et al.</i> , "Biological activities and receptor binding of two human recombinant interferons and their hybrids," <i>J. Gen. Virol.</i> , 67(8):1633-1643, August 1986

**EXAMINER  
SIGNATURE:**
**DATE  
CONSIDERED:**

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

<b>Attorney Docket Number</b>	4239-64129
<b>Application Number</b>	Not yet assigned.
<b>Filing Date</b>	Concurrent herewith
<b>First Named Inventor</b>	Zoon
<b>Art Unit</b>	Not yet assigned.
<b>Examiner Name</b>	Not yet assigned.

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------